Biological properties of a new mixed lanthanide(III) complex incorporating a dypiridinium ylide

Innovative lanthanide complexes: Shaping the future of cancer/ tumor chemotherapy

Developing new therapeutic and diagnostic metals and metal complexes is a stunning example of how inorganic chemistry is rapidly becoming an essential part of modern medicine. More study of bio-coordination chemistry is needed to improve the design of compounds with fewer harmful side effects. Metal-containing drugs are widely utilized in the treatment of cancer. Platinum complexes are effective against some cancers, but new coordination compounds are being created with improved pharmacological properties and a broader spectrum of anticancer action. The coordination complexes of the 15 lanthanides or rare earth elements in the periodic table are crucial for diagnosing and treating cancer. Understanding and treating cancer requires the detection of binding lanthanide (III) ions or complexes to DNA and breaking DNA by these complexes. Current advances in lanthanide-based coordination complexes as anticancer treatments over the past five years are discussed in this study.

Novel electrospun fibers as carriers for delivering a biocompatible Sm(iii) nanodrug for cancer therapy: fabrication, characterization, cytotoxicity and toxicity

The current study represents the successful fabrication and characterization of a Sm(iii) nano complex based on 2-cyano-N'-((4-oxo-4H-chromen-3-yl)methylene)acetohydrazide (CCMA). The fibrous Sm(iii) nanocomplex has been fabricated by the electrospinning technique. SEM analysis of the electrospun fibers has revealed that the fibers have a uniform structure and smooth surface without observing Sm(iii) nanocomplex crystals, i.e. the Sm(iii) nanocomplex has been well incorporated into the fibers. In vitro antitumor activity against two carcinogenic cell lines (HepG-2 and E.A.C.) as well as in vivo toxicity of pure Sm(iii) nanocomplex and its electrospun fibers have been detected. The biological results have shown that there is a significant antitumor activity with low toxicity of the pure Sm(iii) nanocomplex and its electrospun fibers with respect to different standard antitumor drugs. Also, the electrospun fibers recorded higher cytotoxicity (IC₅₀ = 0.1 μM (Hep-G); 0.09 μM (E.A.C)) and lower toxicity (LD₅₀ = 350 mg kg^-1) than the pure ones. The in vitro release rate of the Sm(iii) nanocomplex from electrospun fibers has also been detected. The results have shown that the burst releasing of the Sm(iii) nanocomplex is about 22% after 1 h at the beginning, then a cumulative release increased gradually over the following hours. All results demonstrate the potential use of the Sm(iii) nanocomplex as a potent antitumor drug and its electrospun fibers as superior drug carriers for the treatment of tumors.